Regenxbio (RGNX) Tops Q2 EPS by 18c
Tweet
Share
E-mailGet Alerts RGNX Hot Sheet
Join SI Premium – FREE
Regenxbio (NASDAQ: RGNX) reported Q2 EPS of $0.43, $0.18 better than the analyst estimate of $0.25. Revenue for the quarter came in at $108.02 million versus the consensus estimate of $113.74 million.
For earnings history and earnings-related data on Regenxbio (RGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rockstar Energy founder seeks CEO role at Celsius Holdings
- SpyGlass Pharma (SGP) Reports Q2 Loss of $0.59
- Bimini Capital Management (BMNM) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
